Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Profitability
This table compares Krystal Biotech and Applied Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
Earnings and Valuation
This table compares Krystal Biotech and Applied Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $389.13 million | 25.22 | $204.83 million | $7.98 | 41.56 |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
Krystal Biotech has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Krystal Biotech and Applied Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Krystal Biotech currently has a consensus price target of $377.20, indicating a potential upside of 13.75%. Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics’ higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Applied Therapeutics on 12 of the 15 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Applied Therapeutics
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
